Palo Alto startup 8th Wall launches cross-platform tools for Mobile AR
8th Wall XR provides a single solution for developing AR apps on all iOS and Android phones
PALO ALTO, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- 8th Wall, Inc. announced today 8th Wall XR, the world's first Augmented Reality (AR) platform that works on all commonly available iOS and Android phones and integrates seamlessly with ARKit (Apple) and Tango (Google).
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/51163dc6-2e25-4f8d-a653-d797786f1e26
Founded in August 2016, 8th Wall is a Palo Alto startup made up of an all-star team of ex-Google and Facebook engineers with extensive experience in computer vision, machine learning and product development. Passionate about AR, the team believes that the shift to widespread AR adoption will start with today's mobile phones. As a result they have been working on a suite of native tools that make it effortless to develop AR applications for mobile.
Even with promising native AR frameworks such as ARKit becoming available later this year, current estimates put the availability of native mobile AR frameworks at less than 15% of smartphones in 2018. This severely limits the consumer reach of these applications compared to standard mobile apps.
In contrast, 8th Wall XR provides a cross-platform AR solution that works on any common phone with or without native AR frameworks, proving an estimated 650% increase in the number of supported smartphones. When a phone supports a native framework such as ARKit or Tango, 8th Wall XR uses these libraries to provide 6 Degrees-of-Freedom (DoF) tracking, surface estimation, lighting estimation, and calibrated scene display. For other phones, 8th Wall XR provides 3DoF tracking, fixed surfaces, camera calibration information and vision-based lighting estimation. Later this year the team plans to bring 6 DoF to all supported phones as well, using 8th Wall's vision and machine learning algorithms.
"8th Wall XR works by bringing the best possible AR experience to each user's device," said Erik Murphy-Chutorian, Founder and CEO of 8th Wall. "It leverages native libraries like ARKit or Tango when available, and in their absence as is common today, the very same apps run on all other iOS or Android devices by using the phone's camera and inertial sensors. We've made it much faster to develop as well, addressing the current shortcomings and challenges in building an AR app today. With 8th Wall XR, developers can now effortlessly create an AR application in a matter of minutes."
Beginning today, 8th Wall XR is publicly available to Unity developers at www.8thwall.com and is also available as a native library for iOS and Android per arrangement. The team plans to support additional platforms in the future.
About 8th Wall, Inc.
8th Wall's mission is to break the wall between the digital world and the physical world by creating software that enables developers to quickly and easily build mobile applications that interact with the real world. The 8th Wall team is comprised of proven experts with deep expertise in computer vision, image infrastructure, machine learning and full-stack mobile product development. For more information, please visit www.8thwall.com
8th Wall, 8th Wall, Inc., 8th Wall XR and associated logos are registered trademarks or trademarks of 8th Wall, Inc. and/or its affiliates in the United States and/or other countries. All other trademarks are the property of their respective owners.
The preceding is intended to outline our general product direction. It is intended for information purposes only, and may not be incorporated into any contract. It is not a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. The development, release, and timing of any features or functionality described for 8th Wall's products remain at the sole discretion of 8th Wall, Inc.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: 8th Wall via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
XBiotech to Present at Cantor Fitzgerald's Global Healthcare Conference21.9.2017 14:00 | Pressmeddelande
AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that management will be presenting at Cantor Fitzgerald's Global Healthcare Conference taking place September 25-27 at the InterContinental New York Barclay Hotel in New York City. Mr. Benjamin Guzman, the Company's Senior Vice President of Corporate Strategy & Finance, will provide a corporate overview on Wednesday, September 27th at 2:50pm Eastern Time. About True Human(TM) Therapeutic Antibodies Unlike previous generations of antibody therapies, XBiotech's True Human(TM) antibodies are derived without modification from individuals who possess natural immunity to certain diseases. With discovery and clinical programs across multiple disease areas, XBiotech's True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. About XBiotech
At the 10th anniversary of the iPhone, Chairman of Pilatus Bank draws a stark comparison of the role technology has played in banking vs telecommunication21.9.2017 08:58 | Pressmeddelande
LONDON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Ali Sadr, Chairman of Pilatus Bank, believes that banks have failed to capture the true essence of technology for improving quality of service, as well as lacking the vision necessary to capture customers' imaginations. Meanwhile, other industries have been revolutionized and continue to thrive by the same technology. America has in the last 10 years been forced to close 10,000 branches. Since 2008, Europe has lost close to 48,000 branches, which is more than 20% of its branch network. There is little doubt that branch banking is on the decline, and online banking is failing to provide a quality service. As we mark the 10th anniversary of the iPhone, Ali Sadr, Chairman of Pilatus Bank, gives a sobering count of the current state of affairs in the use of technology among well established banks, and elaborates on a vision that has the potential to become the largest revolution the banking industry is yet to experience. Chairman Al
Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA21.9.2017 08:00 | Pressmeddelande
Pressmeddelande 21 september 2017 Immunicum AB (publ) presenterar prekliniska data om ilixadencels verkningsmekanism på SITC-mötet i USA Immunicum AB (publ; First North Premier: IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörer, meddelar idag att Society for Immunotherapy of Cancer (SITC) har accepterat att ett abstract kring ilixadencels verkningsmekanism presenteras som poster vid SITCs 32:a årsmöte som hålls 8-12 november, 2017 i Gaylord National Hotel & Convention Center i National Harbor, Maryland. Postern med titeln "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" presenteras av Immunicums forskningschef Alex Karlsson-Parra. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande efter presentationen. När datum och tidpunkt för presentationen offentliggjorts kommer detta att fi
Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US21.9.2017 08:00 | Pressmeddelande
Press Release 21 September 2017 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel's Mode of Action at the SITC Meeting in the US Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immune-priming cancer treatment against a variety of solid tumors, today announced that the Society for Immunotherapy of Cancer (SITC) has accepted an abstract on ilixadencel's mode of action for a poster presentation at the SITC 32 nd Annual Meeting, held November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. The poster titled "In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration" will be presented by Immunicum's Chief Scientific Officer, Alex Karlsson-Parra. Immunicum will announce the complete data through a press relea
Asure Software to Attend at Quora Consulting's Smartworking Summit21.9.2017 07:00 | Pressmeddelande
Asure Join's Industry Leaders to Discuss "Understanding the Productivity Enigma" AUSTIN, Texas, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Asure Software, (NASDAQ:ASUR), a leading provider in human capital management and workspace management software, will be sponsoring Quora Consulting's Smartworking Summit in central London, September 28th 2017. These summits have continued to lead in addressing work space issues, such as occupancy, utilization, and productivity in the workforce. Dominic Jackson, Asure Sales Director of EMEA commented, "It is workplace issues like productivity that have driven thought leadership here at Asure." He continued "Utilization of workspace solutions help you recruit and retain the best talent, improve employee productivity, streamline operations, and realize a significant ROI on your most valuable assets - people, space and technology. We are thrilled to be not only part of the discussion, but part of the solu
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure21.9.2017 00:23 | Pressmeddelande
DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the prior FDA Humanitarian Device Exemption (HDE) received in January 2015 and adds the Impella RP heart pump to Abiomed's platform of PMA approved devices. With this approval, the Impella RP heart pump is the only percutaneous temporary ventricular support device that is FDA-approved as safe and effective for right heart failure as stated in the indication: The Impella RP System is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device impl
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum